Compare DHI & A Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DHI | A |
|---|---|---|
| Founded | 1978 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Laboratory Analytical Instruments |
| Sector | Consumer Discretionary | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.6B | 39.8B |
| IPO Year | 1992 | 1999 |
| Metric | DHI | A |
|---|---|---|
| Price | $155.94 | $140.41 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 15 |
| Target Price | $161.00 | ★ $162.80 |
| AVG Volume (30 Days) | ★ 3.1M | 2.2M |
| Earning Date | 01-20-2026 | 11-24-2025 |
| Dividend Yield | ★ 1.15% | 0.73% |
| EPS Growth | N/A | ★ 3.16 |
| EPS | ★ 11.57 | 4.57 |
| Revenue | ★ $34,250,400,000.00 | $6,948,000,000.00 |
| Revenue This Year | $0.88 | $7.76 |
| Revenue Next Year | $5.63 | $6.24 |
| P/E Ratio | ★ $13.52 | $30.56 |
| Revenue Growth | N/A | ★ 6.73 |
| 52 Week Low | $110.44 | $96.43 |
| 52 Week High | $184.55 | $160.27 |
| Indicator | DHI | A |
|---|---|---|
| Relative Strength Index (RSI) | 54.13 | 40.47 |
| Support Level | $154.69 | $139.15 |
| Resistance Level | $158.00 | $143.93 |
| Average True Range (ATR) | 4.34 | 3.89 |
| MACD | 0.30 | -1.39 |
| Stochastic Oscillator | 48.08 | 6.06 |
With operations in 126 markets across 36 states, D.R. Horton is the leading homebuilder in the United States. It mainly builds single-family detached homes (87% of home sales revenue) and offers products to entry-level, move-up, luxury buyers, and active adults. The company offers homebuyers mortgage financing and title agency services through its financial services segment. D.R. Horton's headquarters are in Arlington, Texas, and it manages six regional segments across the United States.
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life science and diagnostic firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools, cross lab consisting of consumables and services related to life science and applied tools, and diagnostics and genomics. Over half of its sales are generated from the biopharmaceutical, chemical, and advanced materials end markets, which we view as the stickiest end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the US and China representing the largest country concentrations.